Assert-IQ vs FFRangio System

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Assert-IQ

by Abbott

FFRangio System

by CathWorks (acquired by Medtronic)

AI Verdict

Assert-IQ is designed for long-term, continuous monitoring and diagnosis of heart rhythm disorders, utilizing an insertable cardiac monitor. In contrast, the FFRangio System focuses on real-time, wire-free assessment of coronary artery disease to guide percutaneous coronary intervention decisions. Therefore, they serve distinct diagnostic and interventional needs within cardiology.

Choose Assert-IQ if…

Choose Assert-IQ if your primary goal is long-term, continuous monitoring for patients with suspected, intermittent, or asymptomatic heart rhythm disorders. This system is ideal for comprehensive arrhythmia detection over several years, enabling remote monitoring and proactive alerts for clinicians.

View Assert-IQ →

Choose FFRangio System if…

Choose FFRangio System if you need real-time, wire-free functional guidance to optimize percutaneous coronary intervention (PCI) decisions in patients with coronary artery disease. This tool is best suited for assessing the hemodynamic significance of coronary lesions directly in the cath lab, providing insights to confirm and refine treatment strategies.

View FFRangio System →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Assert-IQ	FFRangio System
Pricing	Unknown	Contact vendor for pricing information.
Deployment	Subcutaneously implanted device with mobile app connectivity	SaaS, on-prem, hybrid
BAA Available	Unknown	Yes AI-estimated
FDA Status	Cleared AI-estimated	Cleared AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

FFRangio System

Tool B, the FFRangio System, offers significant usability advantages by eliminating the need for invasive pressure wires and drugs during FFR assessment, streamlining the procedure for clinicians and improving the patient experience. Its intuitive user interface and seamless integration with existing cath lab equipment further enhance its operational ease.

Clinical Value

Tie

Both tools provide substantial clinical value within their specialized domains. Assert-IQ offers long-term, continuous cardiac monitoring for arrhythmia detection and management, while the FFRangio System provides accurate, wire-free FFR guidance for optimizing PCI decisions in coronary artery disease. Both are FDA cleared and address critical diagnostic and interventional needs in cardiology.

Pricing & Value

Tie

Both Assert-IQ and the FFRangio System require direct contact for pricing details and do not offer a free trial. Without specific pricing information or transparent value propositions beyond 'contact for pricing,' it is impossible to determine which tool offers better pricing or overall value.

Enterprise Readiness

Assert-IQ

Assert-IQ, from Abbott Medical, explicitly states HIPAA compliance and offers a hybrid deployment model, targeting large health systems. Abbott's established global presence and extensive resources suggest robust enterprise-level support and integration capabilities. While FFRangio has ISO 27001 certification, its HIPAA compliance is not explicitly stated as 'yes' in the provided data, and its deployment is solely on-premise.

Innovation

FFRangio System

The FFRangio System represents a more disruptive innovation by providing wire-free and drug-free 3D FFR guidance, leveraging AI for real-time analysis and eliminating traditional invasive methods. This approach significantly advances coronary physiology assessment. Assert-IQ, while offering advanced features like long-term monitoring and Bluetooth data transmission, builds upon existing insertable cardiac monitor technology.

Support & Docs

Assert-IQ

Assert-IQ is developed by Abbott Medical, a large, globally established medical device company with extensive resources. This typically translates to comprehensive support infrastructure, robust documentation, and a wide service network. CathWorks, while specialized, is a smaller company, and no specific details regarding their support or documentation are provided, making it likely that Abbott offers superior support.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Assert-IQ	FFRangio System
Name	Assert-IQ	FFRangio System
Company	Abbott Medical	CathWorks
Categories	Cardiology AI, Clinical Decision Support & Reference	Cardiology AI, Surgical AI
Specialties	Cardiology, Internal Medicine	Cardiology
Primary Function	Long-term continuous cardiac monitoring and advanced arrhythmia detection.	Wire-free and drug-free 3D FFR guidance for optimizing PCI decisions.
Mobile App	none	Not specified

Videos

Demos, reviews, and walkthroughs featuring Assert-IQ and FFRangio System.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What are the primary clinical applications of Assert-IQ versus the FFRangio System?

Assert-IQ is an insertable cardiac monitor designed for long-term, continuous monitoring and advanced arrhythmia detection to diagnose and manage suspected heart rhythm disorders. The FFRangio System provides wire-free and drug-free 3D FFR guidance to optimize and confirm PCI decisions for patients with coronary artery disease.

How do the patient procedures and invasiveness differ between Assert-IQ and the FFRangio System?

Assert-IQ involves a minimally invasive insertion of a small device just under the skin in the left pectoral region for continuous heart rhythm monitoring. The FFRangio System integrates with existing cath lab equipment and C-arm angiography systems, eliminating the need for invasive pressure wires, drugs, or a guide catheter during coronary artery disease assessment.

What type of diagnostic information and insights does each tool provide?

Assert-IQ offers continuous cardiac monitoring with advanced algorithms for arrhythmia detection, including capabilities for remote monitoring and proactive clinician alerts. The FFRangio System provides real-time FFRangio values at every point on the coronary tree, simulated pullback curves to differentiate functional patterns of CAD, and a Lesion Impact feature to assess residual ischemia.

Which patient populations and medical specialties are primarily targeted by Assert-IQ and the FFRangio System?

Assert-IQ is intended for patients with suspected heart rhythm disorders and is relevant for Cardiology and Internal Medicine specialties. The FFRangio System focuses on patients with coronary artery disease requiring PCI optimization, primarily within Cardiology.

What are the key technological differentiators that set each tool apart?

Assert-IQ features long-term continuous cardiac monitoring for up to six years, advanced arrhythmia detection algorithms, and Bluetooth Low Energy data transmission to a cloud-based platform. The FFRangio System utilizes artificial intelligence to aid in quick angiogram analysis and provides wire-free and drug-free 3D FFR guidance.